Valuation: Elicio Therapeutics, Inc.

Market Cap 82.26M 70.56M 65.89M 60.45M 114M 7.86B 116M 778M 304M 3.94B 309M 302M 13.04B P/E 2026 *
-1.62x
P/E 2027 * -1.45x
Enterprise Value 82.26M 70.56M 65.89M 60.45M 114M 7.86B 116M 778M 304M 3.94B 309M 302M 13.04B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
72.98%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week+0.98%
Current month+10.36%
1 month-0.64%
3 months-66.30%
6 months-65.12%
Current year-61.18%
1 week 2.98
Extreme 2.98
3.36
1 month 2.72
Extreme 2.72
3.36
Current year 2.66
Extreme 2.66
16
1 year 2.66
Extreme 2.66
16
3 years 2.66
Extreme 2.66
16
5 years 2.66
Extreme 2.66
24.39
10 years 2.66
Extreme 2.66
24.39
Manager TitleAgeSince
Chief Executive Officer 66 30/09/2018
Director of Finance/CFO 54 23/03/2025
Chief Tech/Sci/R&D Officer - 18/11/2025
Director TitleAgeSince
Director/Board Member 66 30/09/2018
Director/Board Member 54 31/05/2023
Chairman 71 31/12/2016
Date Insider Type Main position Quantity % Market Cap.
16/07/26 Free

Chief Technology Officer

64,643 0.3387%
16/07/26 Free

Chief Technology Officer

52,832 0.2768%
16/07/26 Free

Chief Executive Officer

186,944 0.9795%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%+0.98%-73.20%-69.10% 82.26M
+1.43%+2.09%+2.20%+24.45% 50.5B
-2.05%+4.50%+483.75%+606.68% 46.01B
-1.41%+4.59%+20.38%+89.87% 42.85B
+2.18%+5.99%+33.30%+19.42% 41.03B
-0.72%-3.91%+17.87%+47.98% 32.02B
+1.32%+6.54%+33.13%+152.05% 16.98B
-1.05%+5.16% - - 17.05B
+2.43%+3.28%+5.20%+34.67% 14.3B
+0.66%+4.42%+84.04%+46.18% 13.84B
Average +0.19%+1.78%+67.41%+105.80% 27.47B
Weighted average by Cap. +0.12%+2.37%+104.71%+151.55%

Financials

2026 *2027 *
Net sales - -
Net income -43.19M -37.05M -34.6M -31.74M -59.69M -4.13B -60.67M -408M -160M -2.07B -162M -159M -6.85B -60.71M -52.08M -48.63M -44.61M -83.9M -5.8B -85.28M -574M -225M -2.91B -228M -223M -9.62B
Net Debt - -
Logo Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of immunotherapies for the treatment of cancer. The Company provides a platform, amphiphile (AMP) that delivers immunotherapeutics directly to the lymph nodes (brain center) of the immune system. The Company’s clinical and preclinical pipeline includes the lymph node targeted therapeutic cancer vaccines ELI-002, which is being evaluated in a Phase II study, designed to stimulate an immune response against mutant kirsten rat sarcoma (KRAS). Its ELI-007 is being evaluated in a preclinical study for the treatment of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) driven cancers, and ELI-008, is being evaluated in a preclinical study for use in the treatment of mutated tumor protein p53 (TP53) expressing cancers.
Employees
33
Date Price Change Volume
13/08/26 US$3.090 -1.90% 155,519
19/08/26 US$3.130 +0.64% 502,610
18/08/26 US$3.110 +2.98% 389,097
17/08/26 US$3.020 -2.27% 253,435
14/08/26 US$3.090 -1.90% 155,519
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.130USD
Average target price
16.50USD
Spread / Average Target
+427.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ELTX Stock